Both A-shares and Hong Kong stocks are now adjusted on Friday morning.
In terms of A-shares, the main indexes further declined, and the ChiNext board and the science and technology innovation board fell in the front.
The "seesaw" effect of the market reappeared, the tourism stocks collectively exploded, the concept of new crown detection fell collectively, and many shares "20 cm" fell to a halt.
In terms of abnormal individual stocks, "Northeast Yaomao" Changchun High-tech has fallen for 3 consecutive trading days.
Hong Kong stocks adjusted slightly after yesterday's sharp rally. On the past Thursday, the Hang Seng Index of Hong Kong stocks rose as much as 3.42% throughout the day, the largest one-day gain in the last 18 months since July 6, 2020.
The "seesaw" effect of A shares reappears: the tourism stocks have collectively exploded The concept of new crown detection has fallen sharply
Market data shows that travel stocks have exploded this morning.
Qujiang Cultural Tourism, Yunnan Tourism, Utrust Tourism, CITS United and other stocks rose and stopped, Jiuhua Tourism, Caissa Tourism and other stocks followed the strengthening, and many tourism ETFs also rose sharply, rising more than 3% intraday.
On the news side, the State Council recently issued the "14th Five-Year Plan" Tourism Development Plan (hereinafter referred to as the "Planning").
The "Plan" proposes seven key tasks. The first is to adhere to innovation-driven development, deepen the "Internet + tourism", and promote the development of smart tourism; the second is to optimize the spatial layout of tourism, promote the coordinated development of urban and rural areas and regions, and build a number of tourist cities and characteristic tourism destinations; the third is to build a scientific protection and utilization system, protect and inherit human resources, and protect and utilize natural resources; the fourth is to improve the tourism product supply system, stimulate the vitality of tourism market players, promote "tourism +" and "+ tourism", and form a new situation of multi-industry integration and development The fifth is to expand the mass tourism consumption system, enhance tourism consumption services, and better meet the multi-level and diversified needs of the people; the sixth is to establish a modern tourism governance system, strengthen the construction of the tourism credit system, and promote civilized tourism; the seventh is to improve the tourism opening and cooperation system, strengthen policy reserves, and continue to promote tourism exchanges and cooperation.
The "Planning" guarantees the implementation from the aspects of strengthening organizational leadership, strengthening policy support, strengthening tourism theory and talent support, and requires each region to formulate tourism development plans or specific implementation plans in combination with the actual conditions of the region, clarify the division of labor, and implement work responsibilities. All departments should, in accordance with the division of responsibilities, strengthen coordination and cooperation, clarify specific measures and work progress, and pay close attention to advancement.
At the same time as the explosion of tourism stocks, the new crown detection concept stocks fell sharply, and many shares fell to a halt, which showed a strong "seesaw" effect with the performance of tourism stocks.
In the concept of new crown detection, Anxu Biological, Oriental Biologics and other shares of "20 cm" fell to a stop. Botuo Biological, Heatscape Biological, Aotai Biological, Shuoshi Biological and other shares fell by more than 10%.
Recently, the big bull stock Jiuan Medical has also sealed the fall stop.
The company issued a stock trading risk warning announcement again last night, saying that the company mentioned the epidemic prevention related plans issued by the US government in the previous announcement, as well as the relevant policies, procurement and distribution plans and situations of the new crown antigen home self-testing agent box products. Investors are requested to note that the above content involves relevant circumstances and procurement is not only for the company, please do not misunderstand the content and mistakenly infer the changes it will bring to the company's performance.
Jiuan Medical also said that the company's stock price is currently at a historical high, and it is not excluded that there is a risk of a decline in the future. Here to remind the majority of investors, the company will strictly implement the relevant provisions of information disclosure of listed companies, timely performance of information disclosure obligations, but also take this opportunity to remind investors again, the Internet platform rumors are many, please investors to the company's official release of information prevail, do not unfoundedly estimate the company's performance and future trends. There are many factors affecting the stock price of the secondary market, and the future development of the epidemic situation in the United States is still uncertain, and the sales of kit products are affected by many factors, please pay attention to investment risks and invest rationally.
On 20 January, the Geneva Drug Patent Pool announced that it had signed agreements with 27 generic drug companies to produce Merck's oral COVID-19 antiviral drug molnupiravir, which will promote the use of this COVID-19 oral drug by patients around the world under an acceptable burden. Among them, there are 5 enterprises in China that are eligible for imitation, including Fosun Pharma, Langhua Pharmaceutical, Longze Pharmaceutical, Brilliant Pharmaceutical, and Disano Pharmaceutical.
Fosun Pharma's A shares rose and stopped this morning, and Bo Rui Pharma's morning "20 cm" limit.
"Northeast Yaomao" fell to a stop for 3 consecutive stops
After the stock price fell to a halt on January 19 and January 20, on the morning of January 21, Changchun Gaoxin, known as "Northeast Medicine Mao", fell to a halt again.
On January 19, the Guangdong Provincial Drug Trading Center issued the "Guangdong Alliance Diclofenac and Other Drugs Centralized Procurement Document" (hereinafter referred to as the "Document"), and 276 drugs were included in the procurement list with quantity, including a number of recombinant human growth hormones.
Changchun Gaoxin said yesterday in the Shenzhen Stock Exchange interactive easy to reply to investors' questions, the company continues to pay attention to the policy changes, the current centralized procurement of drugs has not yet officially started the bidding process, and the specific impact will also depend on the actual participation in the bidding situation, the results of the selection, the price of the selection, etc., the follow-up matters and the degree of impact on the company is still uncertain, there is no expectation of a serious impact on the company's operating performance, the company will actively pay attention to the follow-up progress, carefully study the relevant documents and regulations, and reasonably formulate the implementation plan.
In the process of falling and stopping in the previous two consecutive days, Changchun High-tech has been listed on the Dragon and Tiger List of the Shenzhen Stock Exchange. Dragon and Tiger list data show that institutional seats are sold more. For example, in the Dragon and Tiger list on January 20, 4 seats showed net sales, with a net sale amount of more than 100 million yuan.
It is worth noting that Changchun Gaoxin issued an announcement at noon today that some directors, supervisors and senior management personnel increased their shares in the company, as well as the repurchase results and share change announcements.
The company's announcement disclosed that many directors and supervisors of Changchun High-tech increased their holdings in the company on January 21, 2022 (Note: according to the time of disclosure, that is, this morning). The increase in holdings includes Chairman Ma Ji, Director and General Manager Jiang Yuntao, Director and Executive Deputy General Manager Ye Peng, Director and Deputy General Manager Wang Zhigang, Chairman of the Board of Supervisors Xie Bing, Supervisor Zhao Shuping, Deputy General Manager Li Xiufeng, Deputy General Manager Zhu Xinggong, and Secretary of the Board of Directors Zhang Deshen.
For the purpose of increasing holdings, the announcement said that it is a recognition of the company's long-term value and confidence in the company's future development. The funds for the above-mentioned personnel to increase their shares are self-raised funds, and this increase is the personal behavior of the company's directors, supervisors and senior management.
Hong Kong stocks adjusted slightly in the morning
After yesterday's sharp rise, Hong Kong stocks have adjusted this morning. The Hang Seng Index fell less than 1%.
The Hang Seng Technology Index fell slightly, falling more than 1% intraday.
AAC Technologies and Alibaba Hong Kong stocks both fell by more than 5% in the intraday. NetEase, Sunny Optical Technology, Ping An Good Doctor, Autohome and other declines were in the front.
Overall, however, Hong Kong stocks have not fallen much this morning.
On this past Thursday, Hong Kong stocks experienced a rare surge in more than a year, with the Hang Seng Index rising as much as 3.42% throughout the day, the largest one-day gain in the last 18 months since July 6, 2020.